China Blood Product Industry Report, 2020-2026

Jan.2020

ResearchInChina
www.researchinchina.com

STUDY GOAL AND OBJECTIVES

This report provides the industry executives with strategically significant competitor information, analysis, insight and projection on the competitive pattern and key companies in the industry, crucial to the development and implementation of effective business, marketing and R&D programs.

REPORT OBJECTIVES

- To establish a comprehensive, factual, annually updated and cost-effective information base on market size, competition patterns, market segments, goals and strategies of the leading players in the market, reviews and forecasts.
- To assist potential market entrants in evaluating prospective acquisition and joint venture candidates.
- To complement the organizations' internal competitor information gathering efforts with strategic analysis, data interpretation and insight.
- To suggest for concerned investors in line with the current development of this industry as well as the development tendency.
- To help company to succeed in a competitive market, and

METHODOLOGY

Both primary and secondary research methodologies were used in preparing this study. Initially, a comprehensive and exhaustive search of the literature on this industry was conducted. These sources included related books and journals, trade literature, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. Subsequently, telephone interviews or email correspondence was conducted with marketing executives etc. Other sources included related magazines, academics, and consulting companies.

INFORMATION SOURCES

The primary information sources include Company Reports, and National Bureau of Statistics of China etc.

Abstract

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimbursement from the national medical insurance system. In 2019, the lot release of blood products in China increased further and reached 89.89 million bottles with a year-on-year surge of 21.6%.

Elaborately, the lot release of human albumin rose 17.2% on an annualized basis, making up 58.9%; that of human rabies immunoglobulin soared by 42.9% and accounted for 13.6%; that of human immunoglobulin (pH4) for intravenous injection as a percentage of 13% in the total showed a year-on-year increase of 14.1%; and that of human tetanus immunoglobulin surged by 76.7% and occupied 6.9%.

Other products had small shares, such as human fibrinogen, three kinds of special immunoglobulin, human prothrombin complex, human coagulation factor Ⅷ, particularly coagulation factor category as the lifesaving drug to the victims of hemophilia are often in short supply largely because of the shortage of plasma raw materials domestically as well as the low utilization of plasma.

As the prices of blood products are decontrolled and new plasma stations accelerate to be constructed in recent years, plasma collection in China has been growing year after year, reaching 8,600 tons or more in 2018 with a year-on-year increase of 7.5%. Of all, Beijing Tiantan Biological Products Co., Ltd in possession of 57 plasma stations ranked first by plasma collection up to 1,568.7 tons, a 16.5% share of the total, and its production efficiency gets improved significantly after an asset restructuring.

Number of Plasma Stations and Plasma Collection of Major Chinese Blood Product Enterprises, as of Dec.2019

	Number of Plasma Stations	2016	2017	2018	2019H1
Beijing Tiantan Biological Products	57 (51 ones in operation)	683 tons	862.17 tons	1,568.07 tons	802.55 tons
Shanghai RAAS Blood Products	41	Nearly 900 tons	Over 1,000 tons	1,180 tons	
China Biologic Products Holdings, Inc.	27 (the wholly funded subsidiary Guizhou Taibang with 8 ones, the shareholding subsidiary Shandong Taibang with 16 ones, and the joint-stock company Xi'an Huitian with 3 ones)	About 860 tons	--	--	--
Hualan Biological Engineering	26 (4 in Guangxi,1 in Guizhou, 16 in Chongqing, 5 in Henan)	1000 tons or more	Nearly 1,100 tons		
Southern Shuanglin Bio-Pharmacy	13	Production-use plasma volume 303.9 tons	Production-use plasma volume 322.8 tons	Nearly 400 tons	
Sichuan Yuanda Shuyang Pharmaceutical	15	--	--		
Jiangxi Boya Bio-Pharmaceutical	12	About 250 tons	Plasma collection about 320 tons	350 tons	
Beijing Bohui Innovation Technology	13 (Hebei Daan Pharmaceutical Co., Ltd with 6 ones, Guangdong Wellen Biological Pharmaceutical Co., Ltd with 7 ones)	--	180 tons	235 tons	
Shanxi Kangbao Biological Product	10	--	--		
Weiguang Biological Products	8	319.52 tons	Over 340 tons	360 tons	
Nanyue Biopharming	7	--	--		
Wuhan ZhongyuanRuide Biological Products	4	--	--		
Green Cross China	4	--	--		

Note: Beijing Tiantan Biological Products Co., Ltd's plasma collection in 2018 included those from Lanzhou Lansheng Blood Products, Shanghai Blood Products, Wuhan Bloods Products and Guizhou Blood Products.

Source: ResearchInChina

There are now about thirty blood product enterprises in China, but they are small-sized without rich product portfolios. The industry desires to be concentrated. It is starting from 2008 that the leading players staged mergers and acquisitions and have been developing apace mainly through M&A whilst independently building plasma stations. Meanwhile, some influential companies have turned their attention to overseas resources and good mode and have been actively exploring overseas markets through acquisitions and introducing state-of-the-art technologies from abroad. Undoubtedly, the Chinese market of blood products will get ever concentrated.

What’s more, leading competitors beef up research and development of new products successively and strive to improve comprehensive utilization of plasma. A case in point is the coagulation factorⅧ. Only a few Chinese companies such as China Biologic Products Holdings, Inc., Hualan Biological Engineering Co., Ltd., Shanghai RAAS Blood Products Co., Ltd and Green Cross China are competent to produce the coagulation factorⅧ, but the peers including Jiangxi Boya Bio-Pharmaceutical Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Southern Shuanglin Bio-Pharmacy Co., Ltd. (formerly known as Zhenxing Biopharmaceutical & Chemical Co., Ltd.), Wuhan ZhongyuanRuide Biological Products Co., Ltd., Beijing Bohui Innovation Technology Co., Ltd., Shenzhen Weiguang Biological Products Co., Ltd and Nanyue Biopharming Co., Ltd. are chasing hard and sparing no efforts in the development of the coagulation factorⅧ.

China Blood Product Industry Report, 2020-2026 covers the following:

◆ Blood product market (policy, status quo, market structure, supply & demand, market size and competitive pattern);
◆ Blood product market segments (development, bidding price, competitive landscape);
◆ 13 blood product companies (operation, revenue structure, gross margin and blood product business, etc.);
◆ Summary and forecast.

Table of contents

Table of contents

Table of contents

Room 801, B1, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com

Selected Charts

Selected Charts

Room 801, B1, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com

Selected Charts

Selected Charts

Selected Charts

- R&D Costs of Shanghai RAAS Blood Products, 2013-2019
- Blood Products of Shanghai RAAS Blood Products and Its Subsidiaries
- Output, Sales Volume and Inventory of Blood Products of Shanghai RAAS Blood Products, 2016-2018
- Revenue and Net Income of Tiantan Biological Products, 2013-2019
- Revenue Breakdown of TIANTANBIO (by Product), 2013-2019
- Revenue Structure of TIANTANBIO (by Product), 2013-2019
- Gross Margin of TIANTANBIO (by Product), 2013-2018
- R&D Costs and % of Total Revenue of TIANTANBIO, 2013-2019
- R&D Input of Major Projects of TIANTANBIO, 2018
- Progress of Major R&D Projects of TIANTANBIO, by the End of 2018
- TIANTANBIO's Major Blood Products Subsidiaries and Stake
- Production and Sales of Main Blood Products of TIANTANBIO, 2018
- Lot Release Volume of Main Blood Products of TIANTANBIO, 2015-2019
- Revenue and Net Income of Chengdu Rongsheng Pharmaceutical, 2015-2019
- Revenue and Net Income of Shuanglin Bio-Pharmacy, 2013-2019
- Gross Margin of Shuanglin Bio-Pharmacy, 2013-2019
- R&D Costs and % of Total Revenue of Guangdong Shuanglin Bio-Pharmacy, 2013-2019
- Production-use Plasma Volume of Guangdong Shuanglin Bio-Pharmacy, 2013-2018
- Production, Inventory and Sales of Main Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2013-2018
- Lot Release Volume of Blood Products of Guangdong Shuanglin Bio-Pharmacy, 2015-2019
- Revenue and Net Income of Jiangxi Boya Bio-Pharmaceutical, 2013-2019
- Revenue Breakdown of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2018
- Revenue Structure of Jiangxi Boya Bio-Pharmaceutical (by Business), 2013-2018
- Revenue from Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018
- Revenue Proportion of Major Blood Products of Jiangxi Boya Bio-Pharmaceutical, 2015-2018

Room 801, B1, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com

Selected Charts

Selected Charts

Lot Release Volume of Blood Products of Hebei Da'an Pharmaceutical, 2016-2019
Lot Release Volume of Blood Products of Guangdong Weilun Biological Pharmaceutical, 2016-2019
Development Course of Zhongyuan Ruide Biological Products
Financial Data of Zhongyuan Ruide, 2014-2017
Plasmapheresis Centers of Wuhan ZhongyuanRuide Biological Products, as of Dec.2019
Lot Release Volume of Blood Products of Zhongyuan Ruide Biological Products, 2016-2019
Development History of Sichuan Yuanda Shuyang Pharmaceutical
Specification of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical
Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2016-2018
Plasma Collection Stations of Shanxi Kangbao Biological Product as of Dec. 2019
Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2016-2019
Plasma Collection Stations of Green Cross China as of Jan. 2019
Lot Release Volume of Blood Products of Green Cross China, 2016-2019
Plasmapheresis Centers of Nanyue Biopharming, as of Dec.2019
Lot Release Volume of Blood Products of Nanyue Biopharming, 2016-2018
Market Size of Blood Products in China, 2018-2026E
M&A Cases of Foreign Blood Product Companies
M&A Cases in China Blood Product Industry, 2008-2019
Plasma Collection Volume and YoY Change in China, 2018-2026E
R&D Investment of Major Chinese Blood Product Enterprises, 2014-2019
Population Aged above 60 as a Percentage of Total Population in China, 2009-2018

ResearchInChina

The Vertical Portal for China Business Intelligence

How to Buy

You can place your order in the following alternative ways:

1.Order online at www.researchinchina.com

2.Fax order sheet to us at fax number:+86 10 82601570

3. Email your order to: report@researchinchina.com

4. Phone us at +86 10 82600828

Party A:			
Name:			
Address:			
Contact Person:		Tel	
E-mail:		Fax	

Party B:			
Name:	Beijing Waterwood Technologies Co., Ltd (ResearchInChina)		
Address:	Room 2-626, 6th Floor, No.1, Shanyuan Street, Haidian District, Beijing, 100080		
Contact Person:	Liao Yan	Phone:	86-10-82600828
E-mail:	report@researchinchina.com	Fax:	86-10-82601570
Bank details:	Beneficial Name: Beijing Waterwood Technologies Co., Ltd Bank Name: Bank of Communications, Beijing Branch Bank Address: NO.1 jinxiyuan shijicheng,Landianchang,Haidian District,Beijing Bank Account No #: 110060668012015061217 Routing No # : 332906 Bank SWIFT Code: COMMCNSHBJG		

Title	**Format**	**Cost**
Total		

Choose type of format

PDF (Single user license) …………..3,200 USD

Hard copy ………………….……. 3,400 USD

PDF (Enterprisewide license)…....... 4,800 USD

※ Reports will be dispatched immediately once full payment has been received. Payment may be made by wire transfer or credit card via PayPal.

ResearchInChina

www.researchinchina.com

RICDB service

About ResearchInChina

ResearchInChina (www.researchinchina.com) is a leading independent provider of China business intelligence. Our research is designed to meet the diverse planning and information needs of businesses, institutions, and professional investors worldwide. Our services are used in a variety of ways, including strategic planning, product and sales forecasting, risk and sensitivity management, and as investment research.

Our Major Activities

- ***Multi-users market reports***
- ***Database-RICDB***
- ***Custom Research***
- ***Company Search***

RICDB (http://www.researchinchina.com/data/database.html), is a visible financial data base presented by map and graph covering global and China macroeconomic data, industry data, and company data. It has included nearly 500,000 indices (based on time series), and is continuing to update and increase. The most significant feature of this base is that the vast majority of indices (about 400,000) can be displayed in map.

After purchase of our report, you will be automatically granted to enjoy 2 weeks trial service of RICDB for free.

After trial, you can decide to become our formal member or not. We will try our best to meet your demand. For more information, please find at www.researchinchina.com

For any problems, please contact our service team at: